Show simple item record

dc.date.accessioned2018-06-25T15:09:20Z
dc.date.issued2004
dc.identifierhttp://publications.icr.ac.uk/1738/
dc.identifier.citationLEUKEMIA & LYMPHOMA, 2004, 45 (1), pp. 179 - 181
dc.identifier.issn1042-8194
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1914
dc.description.abstractThalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non- Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness.
dc.format.extent179 - 181
dc.languageeng
dc.language.isoeng
dc.subjectacute myeloid leukaemia (AML) meningeal myelodysplasia non- Hodgkin's lymphoma (NHL) thalidomide acute myelogenous leukemia lymphoid malignancies brain transplantation myelodysplasia therapies
dc.titleThalidomide is highly effective in a patient with meningeal acute myeloid leukaemia
dc.typeJournal Article
rioxxterms.licenseref.startdate2004
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLEUKEMIA & LYMPHOMA
pubs.issue1
pubs.notesnone Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non- Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness.
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume45en_US
pubs.embargo.termsNot known
dc.contributor.icrauthorBaird, Richarden
dc.contributor.icrauthorDuddy, Jamesen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record